IGA IGA
Company Profile ↓Company Overview
IGA (IGA) is a publicly traded company listed on with a market capitalization of $154.18M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 61.9% per year over the last five years.
Revenue has grown at a 59.9% CAGR over the past five years.
Trades at an undemanding P/E of 6.7.
Maintains a net profit margin of 98.7%.
Recent Developments
- Feb 2026 Revenue of $19.14M (-17.7% YoY); net profit $18.89M.
- Trailing 12 Months Year-on-year growth — revenue -17.7%, earnings -17.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 59.9%, profit CAGR 61.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 59.87% |
| 1 Year: | -17.69% |
Compounded Profit Growth
| 5 Years: | 61.92% |
| 1 Year: | -17.93% |
Stock Price Performance
| 1 Year: | +13.21% |
| 6 Months: | +9.69% |
| 3 Months: | +2.32% |
| 1 Month: | -1.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 98.7%.
- Compounding revenue at 59.9% over 5 years.
- Profit CAGR of 61.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Feb 2022 | Feb 2023 | Feb 2024 | Feb 2025 | Feb 2026 |
|---|---|---|---|---|---|
| Revenue | - | 4.68M | 10.94M | 23.25M | 19.14M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 234.48K | 231.13K | 234.20K | 247.67K |
| Operating Income | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | 4.45M | 10.71M | 23.02M | 18.89M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | 4.45M | 10.71M | 23.02M | 18.89M |
| Diluted EPS | 1.38 | 0.32 | 0.74 | 1.51 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2023 | Feb 2024 | Feb 2025 | Feb 2026 |
|---|---|---|---|---|
| Total Assets | 160.72M | 155.03M | 162.03M | 196.61M |
| Current Assets | - | - | - | - |
| Cash & Equivalents | 345.02K | 316.70K | 330.91K | 343.43K |
| Inventory | - | - | - | - |
| Receivables | 1.07M | 343.05K | 1.07M | 31.52M |
| Total Liabilities | 1.49M | 1.72M | 1.76M | 33.10M |
| Current Liabilities | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Total Debt | - | - | - | - |
| Total Equity | 159.23M | 153.31M | 160.27M | 163.51M |
| Shares Outstanding | 15.87M | 15.34M | 15.34M | 15.34M |
Ratios (Annual)
Figures in %.
| Metric | Feb 2022 | Feb 2023 | Feb 2024 | Feb 2025 | Feb 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | 95.0% | 97.9% | 99.0% | 98.7% |
| ROE % | - | 2.8% | 7.0% | 14.4% | 11.6% |
| ROCE % | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IGA
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQRm54NC1tcG9mQlBmUnN2Vkthb1VhcWxQM1JmMnZOT2FFT3FiNFdCTlFKdXE3Q1B0OV95akRUUWt2SFJQcVdkQy12amVXeG9sQTlVZXNGYnkzOVdIYlR1WUxGYkRqd2laRXhjVWkwa05IOXluRHQ5bFdjRmVJWEpCY2NXdTV2dWg0cWI2Zz…
An experimental kidney drug lowered urine protein 43.1% vs placebo at week 37. It is designed for monthly use at home. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPamFmNjFZeFVjZVotVmg4cEU3dzRTNXRYYS1QX0VNb3loUE1QblBMbGlKSWc0cVY4MjdJRUE0V0lWd0RnN2dNeTlCZmM1N2FNQUdsMDl5UnVxMXVCa3A5eXp6UW9oNThKeEthSWlmOHA5UmtZdFZ2TDJ0RzY5T0liYW0wc1VGbFBfdElFWD…
How Voya Global Advantage And Premium Opportunity Fund Of Beneficial Interest (IGA) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiogJBVV95cUxOUG5BMFN4S2k4OFBkMldIeHhlSUxFS3daSmlhejZJN2FpVjBUQ0VQTzNaWXcwTWp5NWVxY2ZHNGZoc1B1dFdYa0lRSjN0YUZMWlVkMTBOam5xX2RGdkxSQ3NTbDVKcUtJY3ZmTkxpaXNkM2RZZXNuZTZDdjdXb0VGdnJFMG12bnJLNUk1a2…
IGA: Shares Push Higher As Discount Narrows (Rating Downgrade) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNa2lwZlFWWElwazY3Z1hPUWlvNGVGMTdpZzhFUzdQWHIwd3hTVm9nNnhWcng4SDlXRXlPY3hRQVF2U013elVjNHlMandoWmJPNVRjdjVyYkZ4b2Q4Tml2WHRVYU41Y0dUNFRpWjFSSWpwUVNBdVJON2g4cnBhZjJScmpTS2xFa0hVYzJB?o…
The Best Resources for IgA Nephropathy (IgAN) - Everyday Health
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQc0lzVHBSbVZFaHBsR3NOajdMLXU1VzdqNENLc043b1g2Mml0WFBRMFN6amJpZkFkczNsajFQcEhGSWl6dkhvRG1HZ1IwUmFCQWN5RWRCNGV6LWJzWFk3UXFsWHltd0VMNGhuUXNoVmUyN1RkQkhxUUJwd1YwVW1wMnR2OWl4cS1qcnFrUG…
IGA Stock Price, Quote & News - Syfe
<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE5uaTNGUEdGQ1VUOW9vQ1N2czVtMHRzTmQxQXVrZF9WdDR5R0t2Y3h1TVp5dkF3TjZPRG9VRVotdkx2Vy1EWTFrUUxn?oc=5" target="_blank">IGA Stock Price, Quote & News</a> <font color="#6f6f6f">…
IGA — Frequently Asked Questions
What is the current share price of IGA?
As of 2026-10-23 16:27 PDT, IGA trades at $10.05 on NASDAQ/NYSE. Its 52-week range is $8.58 to $10.66.
What is the market capitalisation of IGA?
IGA has a market capitalisation of $154.18M on NASDAQ/NYSE.
What is the P/E ratio of IGA?
IGA trades at a trailing price-to-earnings (P/E) ratio of 6.66. Its price-to-book (P/B) ratio is 0.94.
What is the return on equity (ROE) of IGA?
IGA has a return on equity (ROE) of 11.55%.
Is IGA a good stock to buy?
This page provides a data-driven analysis of IGA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.